Recent Advances of Drug Design Strategies for Classical KRAS Mutations

KRAS, one of the most common oncogenic mutations, is considered to be a potential target for design of cancer therapies. Previous studies have suggested a poor therapeutic index and lack of efficacy of drugs targeting the KRAS signalling pathway and even leading to think “undrugged”. But recently, major breakthrough in KRAS was achieved in a decade and even up to hit the market which really inspired a lot. This review aims to illustrate the recent advances of drug design strategies for different types of KRAS mutations, including small molecular inhibitors, PROTAC and others.